Amivantamab, an EGFR and hepatocyte growth factor receptor (MET)-targeted bispecific antibody, has also shown promising efficacy in a multicentre, non-randomized, open label, multicohort CHRYSALIS clinical trial (NCT02609776) involving 81 patients with advanced NSCLC carrying EGFR Ex20ins mutations that have progressed after previous treatment [79]. The gene discussed is MET; the disease is non-small cell lung carcinoma.